Роль ковалентных модификаций в регуляции гена-супрессора опухолевого роста CDKN2A и кодируемого им белка p16-INK4a

Сноски

* Адресат для корреспонденции.

Финансирование

Работа выполнена при поддержке Национального фонда естественных наук Китая (National Natural Science Foundation of China, гранты № 31271442 и 31600645).

Благодарности

Авторы благодарны Baiqu Huang и Jun Lu за критические замечания и полезные советы. Мы также признательны за содействие Central Laboratory, School of Life Sciences, Northeast Normal University.

Конфликт интересов

Авторы заявляют об отсутствии конфликта интересов.

Список литературы

1. Gil, J., and Peters, G. (2006) Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all, Nat. Rev. Mol. Cell Biol., 7, 667–677.

2. Sharpless, N.E. (2005) INK4a/ARF: a multifunctional tumor suppressor locus, Mutat. Res., 576, 22–38.

3. Collado, M., Blasco, M.A., and Serrano, M. (2007) Cellular senescence in cancer and aging, Cell, 130, 223–233.

4. Wang, X., Pan, L., Feng, Y., Wang, Y., Han, Q., Han, L., Han, S., Guo, J., Huang, B., and Lu, J. (2008) P300 plays a role in p16(INK4a) expression and cell cycle arrest, Oncogene, 27, 1894–1904.

5. Russo, A.A., Tong, L., Lee, J.O., Jeffrey, P.D., and Pavletich, N.P. (1998) Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a, Nature, 395, 237–243.

6. Li, J., Poi, M.J., and Tsai, M.D. (2011) Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer, Biochemistry, 50, 5566–5582.

7. Ruas, M., and Peters, G. (1998) The p16INK4a/CDKN2A tumor suppressor and its relatives, Biochim. Biophys. Acta, 1378, 115–177.

8. Ohtani, N., Zebedee, Z., Huot, T.J., Stinson, J.A., Sugimoto, M., Ohashi, Y., Sharrocks, A.D., Peters, G., and Hara, E. (2001) Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence, Nature, 409, 1067–1070.

9. Poi, M.J., Knobloch, T.J., and Li, J. (2017) Deletion of RD(INK4/ARF) enhancer: a novel mutation to «inactivate» the INK4-ARF locus, DNA Repair (Amst.), 57, 50–55.

10. Kotake, Y., Cao, R., Viatour, P., Sage, J., Zhang, Y., and Xiong, Y. (2007) pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene, Genes Dev., 21, 48–54.

11. Bracken, A.P., Kleine-Kohlbrecher, D., Dietrich, N., Pasini, D., Gargiulo, G., Beekman, C., Theilgaard-Monch, K., Minucci, S., Porse, B.T., Marine, J.C., Hansen, K.H., and Helin, K. (2007) The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells, Genes Dev., 21, 525–530.

12. Kotake, Y., Nakagawa, T., Kitagawa, K., Suzuki, S., Liu, N., Kitagawa, M., and Xiong, Y. (2011) Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene, Oncogene, 30, 1956–1962.

13. Yap, KL., Li, S., Munoz-Cabello, A.M., Raguz, S., Zeng, L., Mujtaba, S., Gil, J., Walsh, M.J., and Zhou, M.M. (2010) Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a, Mol. Cell, 38,662–674.

14. Ortega, S., Malumbres, M., and Barbacid, M. (2002) Cyclin D-dependent kinases, INK4 inhibitors and cancer, Biochim. Biophys. Acta, 1602, 73–87.

15. Lang, J.C., Borchers, J., Danahey, D., Smith, S., Stover, D.G., Agrawal, A., Malone, J.P., Schuller, D.E., Weghorst, C.M., Holinga, A.J., Lingam, K., Patel, C.R., and Esham, B. (2002) Mutational status of overexpressed p16 in head and neck cancer: evidence for germline mutation of p16/p14ARF, Int. J. Oncol., 21, 401–408.

16. Kamb, A., Gruis, N.A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S.V., Stockert, E., Day, R.S., Johnson, B.E., and Skolnick, M.H. (1994) A cell cycle regulator potentially involved in genesis of many tumor types, Science, 264, 436-440.

17. Yang, C., Gu, L., and Deng, D. (2014) Distinct susceptibility of induction of methylation of p16ink4a and p19arf CpG islands by X-radiation and chemical carcinogen in mice, Mutat. Res. Genet. Toxicol. Environ. Mutagen., 768, 42–50.

18. Wachter, E., Quante, T., Merusi, C., Arczewska, A., Stewart, F., Webb, S., and Bird, A. (2014) Synthetic CpG islands reveal DNA sequence determinants of chromatin structure, Elife, 3, e03397.

19. Li, L., Li, C., Mao, H., Du, Z., Chan, W.Y., Murray, P., Luo, B., Chan, A.T., Mok, T.S., Chan, F.K., Ambinder, R.F., and Tao, Q. (2016) Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers, Sci. Rep., 6, 26591.

20. Lu, R., Wang, X., Chen, Z.F., Sun, D.F., Tian, X.Q., and Fang, J.Y. (2007) Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells, J. Biol. Chem., 282, 12249–12259.

21. Zhu, B., Gong, Y., Yan, G., Wang, D., Wang, Q., Qiao, Y., Hou, J., Liu, B., and Tang, C. (2017) Atorvastatin treatment modulates p16 promoter methylation to regulate p16 expression, FEBS J., 284, 1868–1881.

22. Yuan, D., Ye, S., Pan, Y., Bao, Y., Chen, H., and Shao, C. (2013) Long-term cadmium exposure leads to the enhancement of lymphocyte proliferation via down-regulating p16 by DNA hypermethylation, Mutat. Res., 757, 125–131.

23. Cui, C., Gan, Y., Gu, L., Wilson, J., Liu, Z., Zhang, B., and Deng, D. (2015) P16-specific DNA methylation by engineered zinc finger methyltransferase inactivates gene transcription and promotes cancer metastasis, Genome Biol., 16, 252.

24. Majid, S., Kikuno, N., Nelles, J., Noonan, E., Tanaka, Y., Kawamoto, K., Hirata, H., Li, L.C., Zhao, H., Okino, S.T., Place, R.F., Pookot, D., and Dahiya, R. (2008) Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification, Cancer Res., 68, 2736–2744.

25. Goto, T., Mizukami, H., Shirahata, A., Sakata, M., Saito, M., Ishibashi, K., Kigawa, G., Nemoto, H., Sanada, Y., and Hibi, K. (2009) Aberrant methylation of the p16 gene is frequently detected in advanced colorectal cancer, Anticancer Res., 29, 275–277.

26. Jablonowski, Z., Reszka, E., Gromadzinska, J., Wasowicz, W., and Sosnowski, M. (2011) Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer, Arch. Med. Sci., 7, 512–516.

27. Zhang, Y., Wang, R., Song, H., Huang, G., Yi, J., Zheng, Y., Wang, J., and Chen, L. (2011) Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer, Cancer Lett., 303, 21–28.

28. Cao, J., Zhou, J., Gao, Y., Gu, L., Meng, H., Liu, H., and Deng, D. (2009) Methylation of p16 CpG island associated with malignant progression of oral epithelial dysplasia: a prospective cohort study, Clin. Cancer Res., 15, 5178–5183.

29. Fujiwara-Igarashi, A., Goto-Koshino, Y., Mochizuki, H., Sato, M., Fujino, Y., Ohno, K., and Tsujimoto, H. (2014) Inhibition of p16 tumor suppressor gene expression via promoter hypermethylation in canine lymphoid tumor cells, Res. Vet. Sci., 97, 60–63.

30. Prueitt, R.L., Goodman, J.E., and Valberg, P.A. (2009) Radionuclides in cigarettes may lead to carcinogenesis via p16(INK4a) inactivation, J. Environ. Radioact., 100, 157–161.

31. Kashiwabara, K., Oyama, T., Sano, T., Fukuda, T., and Nakajima, T. (1998) Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers, Int. J. Cancer, 79, 215–220.

32. Belinsky, S.A. (2005) Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer, Carcinogenesis, 26, 1481–1487.

33. Kaneto, H., Sasaki, S., Yamamoto, H., Itoh, F., Toyota, M., Suzuki, H., Ozeki, I., Iwata, N., Ohmura, T., Satoh, T., Karino, Y., Satoh, T., Toyota, J., Satoh, M., Endo, T., Omata, M., and Imai, K. (2001) Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus, Gut, 48, 372–377.

34. Bian, Y.S., Osterheld, M.C., Fontolliet, C., Bosman, F.T., and Benhattar, J. (2002) p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett’s esophagus, Gastroenterology, 122, 1113–1121.

35. Hardie, L.J., Darnton, S.J., Wallis, Y.L., Chauhan, A., Hainaut, P., Wild, C.P., and Casson, A.G. (2005) p16 expression in Barrett’s esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations, Cancer Lett., 217, 221–230.

36. Alabert, C., and Groth, A. (2012) Chromatin replication and epigenome maintenance, Nat. Rev. Mol. Cell Biol., 13, 153–167.

37. Alaskhar Alhamwe, B., Khalaila, R., Wolf, J. von, Bulow, V., Harb, H., Alhamdan, F., Hii, C.S., Prescott, S.L., Ferrante, A., Renz, H., Garn, H., and Potaczek, D.P. (2018) Histone modifications and their role in epigenetics of atopy and allergic diseases, Allergy Asthma Clin. Immunol., 14, 39.

38. Margueron, R., and Reinberg, D. (2010) Chromatin structure and the inheritance of epigenetic information, Nat. Rev. Genet., 11, 285–296.

39. Wang, X., Feng, Y., Xu, L., Chen, Y., Zhang, Y., Su, D., Ren, G., Lu, J., and Huang, B. (2008) YY1 restrained cell senescence through repressing the transcription of p16, Biochim. Biophys. Acta, 1783, 1876–1883.

40. Feng, Y., Wang, X., Xu, L., Pan, H., Zhu, S., Liang, Q., Huang, B., and Lu, J. (2009) The transcription factor ZBP-89 suppresses p16 expression through a histone modification mechanism to affect cell senescence, FEBS J., 276, 4197–4206.

41. Hyun, K., Jeon, J., Park, K., and Kim, J. (2017) Writing, erasing and reading histone lysine methylations, Exp. Mol. Med., 49, e324.

42. Yoruker, E.E., Mert, U., Bugra, D., Yamaner, S., and Dalay, N. (2012) Promoter and histone methylation and p16(INK4A) gene expression in colon cancer. Exp. Ther. Med., 4, 865–870.

43. Stoll, S., Wang, C., and Qiu, H. (2018) DNA methylation and histone modification in hypertension, Int. J. Mol. Sci., 19, E1174.

44. Kondo, Y., Shen, L., and Issa, J.P. (2003) Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer, Mol. Cell Biol., 23, 206–215.

45. Ito, T., Teo, Y.V., Evans, S.A., Neretti, N., and Sedivy, J.M. (2018) Regulation of cellular senescence by polycomb chromatin modifiers through distinct DNA damage- and histone methylation-dependent pathways, Cell Rep., 22, 3480–3494.

46. Kotake, Y., Naemura, M., Murasaki, C., Inoue, Y., and Okamoto, H. (2015) Transcriptional regulation of the p16 tumor suppressor gene, Anticancer Res., 35, 4397–4401.

47. Ren, C., Smith, S.G., Yap, K., Li, S., Li, J., Mezei, M., Rodriguez, Y., Vincek, A., Aguilo, F., Walsh, M.J., and Zhou, M.M. (2016) Structure-guided discovery of selective antagonists for the chromodomain of polycomb repressive protein CBX7, ACS Med. Chem. Lett., 7, 601–605.

48. Culerrier, R., Carraz, M., Mann, C., and Djabali, M. (2016) MSK1 triggers the expression of the INK4AB/ARF locus in oncogene-induced senescence, Mol. Biol. Cell, 27, 2726–2734.

49. Meng, C.F., Zhu, X.J., Peng, G., Dai, D.Q. (2009) Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells, Oncol. Rep., 22, 1221–1227.

50. Ding, R., Jin, Y., Liu, X., Ye, H., Zhu, Z., Zhang, Y., Wang, T., and Xu, Y. (2017) Dose- and time-effect responses of DNA methylation and histone H3K9 acetylation changes induced by traffic-related air pollution, Sci. Rep., 7, 43737.

51. Thambirajah, A.A., Ng, M.K., Frehlick, L.J., Li, A., Serpa, J.J., Petrotchenko, E.V., Silva-Moreno, B., Missiaen, K.K., Borchers, C.H., Adam Hall, J., Mackie, R., Lutz, F., Gowen, B.E., Hendzel, M., Georgel, P.T., and Ausio, J. (2012) MeCP2 binds to nucleosome free (linker DNA) regions and to H3K9/H3K27 methylated nucleosomes in the brain, Nucleic Acids Res., 40, 2884–2897.

52. Nady, N., Lemak, A., Walker, J.R., Avvakumov, G.V., Kareta, M.S., Achour, M., Xue, S., Duan, S., Allali-Hassani, A., Zuo, X., Wang, Y.X., Bronner, C., Chedin, F., Arrowsmith, C.H., and Dhe-Paganon, S. (2011) Recognition of multivalent histone states associated with heterochromatin by UHRF1 protein, J. Biol. Chem., 286, 24300–24311.

53. Meng, C.F., Zhu, X.J., Peng, G., and Dai, D.Q. (2009) Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells, Oncol. Rep., 22, 1221–1227.

54. Hinshelwood, R.A., Melki, J.R., Huschtscha, L.I., Paul, C., Song, J.Z., Stirzaker, C., Reddel, R.R., and Clark, S.J. (2009) Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning, Hum. Mol. Genet., 18, 3098–3109.

55. Chang, P.B., Choi, K., Moon, Y., Lee, H.Y., and Park, H. (2016) Hypoxic reprograming of H3K27me3 and H3K4me3 at the INK4A locus, FEBS Lett., 19, 3407–3415.

56. Li, J., Poi, M.J., and Tsai, M.D. (2011) Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer, Biochemistry, 50, 5566–5582.

57. Sandhu, C., Peehl, D.M., and Slingerland, J. (2000) p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells, Cancer Res., 60, 2616–2622.

58. Gump, J., Stokoe, D., and McCormick, F. (2003) Phosphorylation of p16INK4A correlates with Cdk4 association, J. Biol. Chem., 278, 6619–6622.

59. Al-Khalaf, H.H., Hendrayani, S.F., and Aboussekhra, A. (2011) The atr protein kinase controls UV-dependent upregulation of p16INK4A through inhibition of Skp2-related polyubiquitination/degradation, Mol. Cancer Res., 9, 311–319.

60. Guo, Y., Yuan, C., Weghorst, C.M., and Li, J. (2010) IKKbeta specifically binds to P16 and phosphorylates Ser8 of P16, Biochem. Biophys. Res. Commun., 393, 504–508.

61. Wang, X., Huang, Y., Zhao, J., Zhang, Y., Lu, J., and Huang, B. (2012) Suppression of PRMT6-mediated arginine methylation of p16 protein potentiates its ability toarrest A549 cell proliferation, Int. J. Biochem. Cell Biol., 44, 2333–2341.

62. Lu, Y., Ma, W., Li, Z., Lu, J., and Wang, X. (2017) The interplay between p16 serine phosphorylation and arginine methylation determines its function in modulating cellular apoptosis and senescence, Sci. Rep., 7, 41390.

63. Lilischkis, R., Sarcevic, B., Kennedy, C., Warlters, A., and Sutherland, R.L. (1996) Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity, Int. J. Cancer, 66, 249–254.

64. Mori, T., Miura, K., Aoki, T., Nishihira, T., Mori, S., and Nakamura, Y. (1994) Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma, Cancer Res., 54, 3396–3397.

65. Soufir, N., Avril, M. F., Chompret, A., Demenais, F., Bombled, J., Spatz, A., Stoppa-Lyonnet, D., Benard, J., and Bressac-de Paillerets, B.(1998) Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group, Hum. Mol. Genet., 7, 209–216.

66. Yakobson, E., Shemesh, P., Azizi, E., Winkler, E., Lassam, N., Hogg, D., Brookes, S., Peters, G., Lotem, M., Zlotogorski, A., Landau, M., Safro, M., Shafir, R., Friedman, E., and Peretz, H. (2000) Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families, Eur. J. Hum. Genet., 8, 590–596.

67. Debniak, T., Scott, R.J., Huzarski, T., Byrski, T., Rozmiarek, A., Debniak, B., Gorski, B., Cybulski, C., Medrek, K., Mierzejewski, M., Masojc, B., Matyjasik, J., Zlowocka, E., Teodorczyk, U., Lener, M., Klujszo-Grabowska, E., Nej-Wolosiak, K., Jaworowska, E., Oszutowska, D., Szymanska, A., Szymanska, J., Castaneda, J., van de Wetering, T., Suchy, J., Kurzawski, G., Oszurek, O., Narod, S., and Lubinski, J. (2006) CDKN2A common variant and multi-organ cancer risk – a population-based study, Int. J. Cancer, 118, 3180–3182.

68. Scaini, M.C., Rossi, E., de Siqueira Torres, P.L., Zullato, D., Callegaro, M., Casella, C., Quaggio, M., Agata, S., Malacrida, S., Chiarion-Sileni, V., Vecchiato, A., Alaibac, M., Montagna, M., Mann, G.J., Menin, C., and D’Andrea, E. (2009) Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation, Mutat. Res., 671, 26–32.

69. Ruas, M., Brookes, S., McDonald, N.Q., and Peters, G. (1999) Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information, Oncogene, 18, 5423–5434.